Clinical pharmacology of dopamine agonists

Pharmacotherapy

Volumn 20, Issue 1 II, 2000, Pages

  Francis Lam, Y W ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; RECEPTOR SUBTYPE; ROPINIROLE;

DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG STRUCTURE; FATIGUE; HUMAN; NAUSEA; PARKINSON DISEASE; RECEPTOR AFFINITY; REVIEW; VOMITING;

EID: 0343938836     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.2.17s.34627     Document Type: Review

References (57)

1. Seeman P, van Tol HHM. Dopamine receptor pharmacology. Trends Pharmacol Sci 1994;15:264-70.
2. De Keyser J. Subtypes and localization of dopamine receptors in human brain. Neurochem Int 1993;22:83-93.
3. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature 1979;277:93-6.
4. 2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse 1995;19:264-93.
5. Calne DB. Treatment of Parkinson's disease. N Engl J Med 1993;329:1021-7.
6. 1 dopamine receptor activity of antiparkinsonian drugs. Life Sci 1997;60:1597-1603.
7. Carfagna N, Caccia C, Buonamici N, et al. Biochemical and pharmacological studies on cabergoline, a new putative antiparkinsonian drug. Soc Neurosci Abstr 1991;17:1075.
8. Mierau J. Pramipexole: a dopamine-receptor agonist for treatment of Parkinson's disease. Clin Neuropharmacol 1995;18(suppl 1):S195-206.
9. Piercy MF, Hoffmann WE, Smith MW, et al. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine agonists. Eur J Pharmacol 1996;312:35-44.
10. 2 agonist. Pharmacol Biochem Behav 1991;38: 147-54.
11. Colosimo C, Merello M, Albanese A. Clinical usefulness of apomorphine in movement disorders. Clin Neuropharmacol 1994;17:243-59.
12. Goetz GG, Diederich NJ. Dopaminergic agonists for the treatment of Parkinson's disease. Neurol Clin 1992;10:527-40.
13. Uitti RJ, Ahlskog JE. Comparative review of dopamine receptor agonists in Parkinson's disease. CNS Drugs 1996;5:369-87.
14. Montastruc JL, Rascol O, Senard JM, et al. A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five-year follow-up. J Neurol Neurosurg Psychiatry 1994;57:1034-8.
15. Hely MA, Morris JGL, Reid WGJ, et al. The Sydney multicenter study of Parkinson's disease: a report on the first three years. J Neurol Neurosurg Psychiatry 1994;57:324-8.
16. Eisler T, Hall RP, Kalaver K, et al. Erythromelalgia-like eruption in parkinsonian patients treated with bromocriptine. Neurology 1981;31:1368-70.
17. Melmed S, Braunstein GD. Bromocriptine and pleuropulmonary disease. Arch Intern Med 1989;149:258-9.
18. Demonet JF, Rostin M, Dueymes M, et al. Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of bromocriptine. Clin Neuropharmacol 1986;9:200-1.
19. Rubin A, Lemberger L, Dhahir P. Physiologic disposition of pergolide. Clin Pharmacol Ther 1981;30:258-65.
20. Schran HF, Bhuta SI, Schwarz HJ, et al. The pharmacokinetics of bromocriptine in man. Adv Biochem Psychopharmacol 1980;23:125-39.
21. Maurer G, Schreier E, Delaborde S, et al. Fate and disposition of bromocriptine in animals and man. II. Absorption, elimination and metabolism. Eur J Drug Metab Pharmacokinet 1983;8:51-62.
22. Cotzias GC, Papavasiliou PS, Tolosa ES, et al. Treatment of Parkinson's disease with apomorphine. N Engl J Med 1976;294:567-72.
23. Gancher ST, Nutt JG, Woodward WR. Absorption of apomorphine by various routes in parkinsonism. Mov Disord 1991;6:212-16.
24. Gancher ST, Woodward WR, Boucher B, et al. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol 1989;26:232-8.
25. Pharmacia & Upjohn Company. Data on file. Kalamazoo, MI;1996.
26. Brefel C, Thalamas C, Rayet S, et al. Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients. Br J Clin Pharmacol 1998;45:412-15.
27. Persiani S, Rocchetti M, Pacciarini MA, et al. The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers. Biopharm Drug Dispos 1996;17:443-55.
28. Mico BA, Swagzdis JE, Federowicz DA, et al. Functional group metabolism of dopamine-2 agonists: conversion of 4-(2-di-n-propylaminoethyl)-2-(3H)-indolone to 4-(2-di-n-propylaminoethyl)-7-hydroxy-2-(3H)-indolone. J Pharm Sci 1985;75:929-33.
29. Persiani S, Sassolas G, Piscitelli G, et al. Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers. J Pharm Sci 1994;83:1421-5.
30. 3H] cabergoline in man. Drug Metab Drug Interact 1992;10:199-211.
31. Bloomer JC, Clarke SE, Chenery RJ. In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole. Drug Metab Dispos 1997;25:840-4.
32. Peters GR, Francom SF, Wright CE. Dopamine agonist dose escalation in healthy volunteers: time course of tolerance development to pramipexole effects [abstr]. Clin Pharmacol Ther 1996;59:178.
33. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995;18:338-47.
34. Taylor AC, Beerahee A, Citerone DR, et al. Linear pharmacokinetics of ropinirole in patients with Parkinson's disease [abstr]. Br J Clin Pharmacol 1998;45:204P.
35. Wright CE, Sission TL, Ichhpurani AK, et al. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol 1997;37:520-5.
36. Shannon KM, Bennett JP, Friedman JH, et al. Efficacy of pramipexole, a novel dopamine agonist as monotherapy in mild to moderate Parkinson's disease. Neurology 1997;49:724-8.
37. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson's disease. A randomized dose-ranging study JAMA 1997;278:125-30.
38. Martinez-Martin P, Gil-Nagel A, Gracia LM, et al. Unified Parkinson's disease raling scale characteristics and structure. Mov Disord 1994;9:76-83.
39. Molho ES, Facotr SA, Weiner WJ, et al. The use of pramipexole, a novel dopamine agonist, in advanced Parkinson's disease. J Neural Transm 1995;45(suppl):225-30.
40. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997;49:393-9.
41. Rascol O, Brooks DJ, Brunt ER, et al. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. Mov Disord 1998;13:39-45.
42. Korczyn AD, Brooks DJ, Brunt ER, et al. Ropinirole vs bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. Mov Disord 1998;13:46-51.
43. 2 agonist, as an adjunct to L-dopa (DCl) in patients with Parkinson's disease [abstr]. Mov Disord 1996;11(suppl 1):156.
44. Rascol O, and the Parkinson's Disease A double-blind L-dopa controlled study of ropinirole in de novo patients with Parkinson's disease [abstr]. Mov Disord 1996; 11(suppl 1):139.
45. Rinne UK, Bracco F, Chouza C, et al. Cabergoline in the early treatment of Parkinson's disease: results of the first year of treatment in a double-blind study of cabergoline and levodopa. Neurology 1997;48:363-8.
46. Inzelberg R, Nisipeanu P, Rabey JM, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuation. Neurology 1996;47:785-8.
47. Lera G, Vaamonde J, Rodriguez M, et al. Cabergoline in Parkinson's disease: long-term follow up. Neurology 1993;43:2587-90.
48. Hutton JT, Koller WC, Ahlskog JE, et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology 1996;46:1062-5.
49. Clemens JA, Shaar CJ, Smalstig EB, et al. Inhibition of prolactin secretion by ergolines. Endocrinology 1974;94:1171-6.
50. Schilling JC, Adaus WS, Palluk R. Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans. Clin Pharmacol Ther 1992;51:541-8.
51. 2-receptor agonist. Br J Clin Pharmacol 1989;28:435-41.
52. Brooks DJ, Torjanski N, Burn DJ. Ropinirole in the symptomatic treatment of Parkinson's disease. J Neural Transm 1995;45:231-8.
53. Wynalda MA, Wienkers LC. Assessment of potential interactions between dopamine receptor agonists and various cytochrome P-450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos 1997;25:1211-14.
54. Pharmacia & Upjohn Company. Technical report on file. Kalamazoo, MI;April 1996.
55. Wright CE, Sissson TL, Ichhpurani BA, et al. Influence of probenecid and cimetidine on pramipexole pharmacokinetics [abstr]. Clin Pharmacol Ther 1996;59:183.
56. SmithKline Beecham Pharmaceuticals. Requip prescribing information. Philadelphia, PA;1997.
57. 2-receptor agonist Br J Clin Pharmacol 1991;32:483-8.